• Something wrong with this record ?

Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT study

D. Jäger, JH. Ma, J. Mardiak, DW. Ye, E. Korbenfeld, M. Zemanova, H. Ahn, J. Guo, N. Leonhartsberger, K. Stauch, A. Böckenhoff, J. Yu, B. Escudier,

. 2015 ; 13 (2) : 156-64.e1. [pub] 20140823

Language English Country United States

Document type Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16000512

BACKGROUND: Patients with advanced renal cell carcinoma in routine clinical practice can differ considerably from those in phase III studies. PATIENTS AND METHODS: PREDICT (Patient characteristics in REnal cell carcinoma and Daily practICe Treatment with sorafenib) was a prospective, noninterventional study of open-label sorafenib for the treatment of advanced RCC conducted in 18 countries. Patient characteristics, therapy duration, tumor status, and tolerability were assessed at baseline and during routine follow-up. RESULTS: Overall, 2599 patients were evaluable for safety and 2311 for efficacy. The diverse population included patients with brain metastases (5%), non-clear-cell histologies (17%), high Memorial Sloan-Kettering Cancer Center risk score (11%), poor Eastern Cooperative Oncology Group performance status (PS ≥ 2, 29%), and patients with no previous nephrectomy (16%) or no previous systemic therapy (37%). The median duration of sorafenib therapy was 7.3 months and was similar in clinically relevant subgroups (eg, patients with PS 2, brain metastases, or concomitant hypertension or diabetes [range, 6.7-7.0 months]). The median duration of therapy was shorter for patients with PS 3 or non-clear-cell histologies (4.6 and 4.8 months, respectively). The most common drug-related adverse events were hand-foot skin reaction (20%), diarrhea (17%), and rash (8%). CONCLUSION: Sorafenib was generally well tolerated and provided clinical benefit in a large, diverse population of patients with advanced RCC treated in routine clinical practice.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16000512
003      
CZ-PrNML
005      
20160516100318.0
007      
ta
008      
160108s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.clgc.2014.07.007 $2 doi
035    __
$a (PubMed)25444666
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Jäger, D $u National Center for Tumor Diseases, University Medical Center Heidelberg, Heidelberg, Germany. Electronic address: dirk.jaeger@nct-heidelberg.de.
245    10
$a Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT study / $c D. Jäger, JH. Ma, J. Mardiak, DW. Ye, E. Korbenfeld, M. Zemanova, H. Ahn, J. Guo, N. Leonhartsberger, K. Stauch, A. Böckenhoff, J. Yu, B. Escudier,
520    9_
$a BACKGROUND: Patients with advanced renal cell carcinoma in routine clinical practice can differ considerably from those in phase III studies. PATIENTS AND METHODS: PREDICT (Patient characteristics in REnal cell carcinoma and Daily practICe Treatment with sorafenib) was a prospective, noninterventional study of open-label sorafenib for the treatment of advanced RCC conducted in 18 countries. Patient characteristics, therapy duration, tumor status, and tolerability were assessed at baseline and during routine follow-up. RESULTS: Overall, 2599 patients were evaluable for safety and 2311 for efficacy. The diverse population included patients with brain metastases (5%), non-clear-cell histologies (17%), high Memorial Sloan-Kettering Cancer Center risk score (11%), poor Eastern Cooperative Oncology Group performance status (PS ≥ 2, 29%), and patients with no previous nephrectomy (16%) or no previous systemic therapy (37%). The median duration of sorafenib therapy was 7.3 months and was similar in clinically relevant subgroups (eg, patients with PS 2, brain metastases, or concomitant hypertension or diabetes [range, 6.7-7.0 months]). The median duration of therapy was shorter for patients with PS 3 or non-clear-cell histologies (4.6 and 4.8 months, respectively). The most common drug-related adverse events were hand-foot skin reaction (20%), diarrhea (17%), and rash (8%). CONCLUSION: Sorafenib was generally well tolerated and provided clinical benefit in a large, diverse population of patients with advanced RCC treated in routine clinical practice.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a ambulantní zařízení $7 D000554
650    _2
$a protinádorové látky $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000970
650    _2
$a karcinom z renálních buněk $x farmakoterapie $x etnologie $x patologie $7 D002292
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a nádory ledvin $x farmakoterapie $x etnologie $x patologie $7 D007680
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a niacinamid $x aplikace a dávkování $x škodlivé účinky $x analogy a deriváty $x terapeutické užití $7 D009536
650    _2
$a fenylmočovinové sloučeniny $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D010671
650    _2
$a prospektivní studie $7 D011446
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ma, J H $u Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China.
700    1_
$a Mardiak, J $u National Cancer Institute, Bratislava, Slovakia.
700    1_
$a Ye, D W $u Affiliated Cancer Hospital of Fudan University, Shanghai, China.
700    1_
$a Korbenfeld, E $u Hospital Británico de Buenos Aires, Buenos Aires, Argentina.
700    1_
$a Zemanova, M $u Charles University in Prague, First Faculty of Medicine, Prague, Czech Republic.
700    1_
$a Ahn, H $u Asan Medical Center, Seoul, Korea. $7 gn_A_00002499
700    1_
$a Guo, J $u Beijing Cancer Hospital, Beijing, China.
700    1_
$a Leonhartsberger, N $u Department of Urology, Medical University Innsbruck, Innsbruck, Austria.
700    1_
$a Stauch, K $u Bayer HealthCare, Leverkusen, Germany.
700    1_
$a Böckenhoff, A $u Bayer HealthCare, Wuppertal, Germany.
700    1_
$a Yu, J $u Bayer HealthCare, Montville, NJ.
700    1_
$a Escudier, B $u Institut Gustave Roussy, Villejuif, France.
773    0_
$w MED00188741 $t Clinical genitourinary cancer $x 1938-0682 $g Roč. 13, č. 2 (2015), s. 156-64.e1
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25444666 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160108 $b ABA008
991    __
$a 20160516100428 $b ABA008
999    __
$a ok $b bmc $g 1102793 $s 924718
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 13 $c 2 $d 156-64.e1 $e 20140823 $i 1938-0682 $m Clinical genitourinary cancer $n Clin Genitourin Cancer $x MED00188741
LZP    __
$a Pubmed-20160108

Find record

Citation metrics

Archiving options